Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: One-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines

Vaccine

Volumn 27, Issue 51, 2009, Pages 7162-7166

  Quiambao, Beatriz P ^a   Dy Tioco, Hazel Z ^b   Dizon, Ruby M ^b   Crisostomo, Marilyn E ^c   Teuwen, Dirk E ^d  

^a Research Institute for Tropical Medicine (RITM)   (Philippines)

^b Sanofi Pasteur   (Philippines)

^c UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^d SANOFI PASTEUR   (France)

Author keywords

Philippines; Post exposure prophylaxis (PEP); Purified equine rabies immunoglobulin (pERIG); Rabies

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; FAVIRAB; RABIES IMMUNOGLOBULIN; RABIES VACCINE; TETANUS ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG EFFICACY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW UP; HEART INFARCTION; HUMAN; INFANT; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PHILIPPINES; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RABIES; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT; WOUND CARE;

ADOLESCENT; ADULT; AGED; ANIMALS; BITES AND STINGS; CHILD; CHILD, PRESCHOOL; DOGS; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HORSES; HUMANS; IMMUNOGLOBULINS; INFANT; MALE; MIDDLE AGED; PHILIPPINES; POST-EXPOSURE PROPHYLAXIS; PROSPECTIVE STUDIES; RABIES; RABIES VACCINES; YOUNG ADULT;

EID: 71849106565     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.036     Document Type: Article

References (10)

1. Rupprecht C.E., Hanlon C.A., and Hemachudha T. Rabies re-examined. Lancet Infect Dis 2 (2002) 327-343
2. Hemachudha T., Wacharapluesdadee S., Laothamatasj, and Wilde H. Rabies. Curr Neurol Neurosci Rep 6 (2006) 460-468
3. Wilde H., Hemachudha T., and Jackson A.C. Viewpoint: management of human rabies. Trans R Soc Trop Med Hyg 102 (2008) 979-982
4. Knobel D.L., Cleaveland S., Coleman P.G., Fèvre E.M., Meltzer M.I., Miranda M.E., et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 83 (2005) 360-368
5. Alliance for Rabies Control. Rabies facts. http://www.rabiescontrol.net/EN/About-Rabies/Rabies-Facts.html; 2009 [accessed 05.06.09].
6. Rabies vaccines. WHO position paper. WER 2008;82:425-36.
7. Rupprecht C.E., and Gibbons R.V. Clinical practice prophylaxis against rabies. N Engl J Med 351 (2004) 2626-2635
8. Quiambao B.P., DyTioco H.Z., Dizon R.M., Crisostomo M.E., Laot T.M., and Teuwen D.E. Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab′)(2) fragment rabies immunoglobulin (Favirab). PLoS Negl Trop Dis 2 (2008) e243
9. Lang J., Attanath P., Quiambao B., Singhasivanon V., Chanthavanich P., Montalban C., et al. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. Acta Trop 70 (1998) 317-333
10. Robles C.G., and Miranda N.L.J. Comparative evaluation of the rabies fluorescent antibody test and direct microscopic examination at the Research Institute for Tropical Medicine. Phil J Microbiol Infect Dis 21 (1992) 69-72